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Abstract
Background: Constipation is a significant problem in the elderly, specifically nursing home and/or extended-care
facility residents are reported to suffer from constipation. Lactic acid bacteria (LAB) are beneficial probiotic
organisms that contribute to improved nutrition, microbial balance, and immuno-enhancement of the intestinal
tract, as well as diarrhea and constipation effect. The objective of this study was to investigate the efficacy of this
LAB supplement in the management of nursing home residents.
Methods: Nineteen subjects (8M, 11F; mean age 77.1 ± 10.1) suffering with chronic constipation were assigned to
receive LAB (3.0 × 1011 CFU/g) twice (to be taken 30 minutes after breakfast and dinner) a day for 2 weeks in
November 2008. Subjects draw up a questionnaire on defecation habits (frequency of defecation, amount and
state of stool), and we collected fecal samples from the subjects both before entering and after ending the trial, to
investigate LAB levels and inhibition of harmful enzyme activities. Results were tested with SAS and Student’s t-test.
Results: Analysis of questionnaire showed that there was an increase in the frequency of defecation and amount
of stool excreted in defecation habit after LAB treatment, but there were no significant changes. And it also affects
the intestinal environment, through significantly increase (p < 0.05) fecal LAB levels. In addition, tryptophanase and
urease among harmful enzyme activities of intestinal microflora were significantly decreased (p < 0.05) after LAB
treatment.
Conclusion: LAB, when added to the standard treatment regimen for nursing home residents with chronic
constipation, increased defecation habit such as frequency of defecation, amount and state of stool. So, it may be
used as functional probiotics to improve human health by helping to prevent constipation.
Background
Constipation is prevalent in modern societies and is a
common symptom in clinical practice [1].
Constipation involves the large intestine and is a
symptom rather than a disease. It is characterized by a
constellation of symptoms and complaints, the most
common of which are low defecation frequency (e.g. less
than 3/week), irregular stool expulsion, painful and
strained defecation, hard and dry stool consistency, a
feeling of incomplete rectal defecation, and passing of
abnormally small stools (e.g. less than 50 g/day) [2].
The prevalence of constipation and its impact on qual-
ity of life are most significant among elderly individuals,
with a reported incidence among ambulatory adults 65
years of age and older of 26% in men and 34% in women.
The prevalence of constipation is usually higher among
elderly people living in nursing homes and hospitals than
those living in the community. Once admitted, other fac-
tors may contribute to constipation (eg, changes in food
and action, lack of exercise, loss of privacy or personality
factors). More than 80% of nursing home and/or
extended-care facility residents are reported to suffer
from constipation. This population includes persons with
higher frequency of risk factors (immobility, polyphar-
macy, and chronic medical conditions).
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Dementia was reported as a risk factor for constipa-
tion, and such residents may be more difficult to man-
age than cognitively intact patients [3]. Other risk
factors for constipation include the use of certain drugs
(eg, anticholinergic antidepressants, opioid analgesics,
and nonsteroidal anti-inflammatory drugs [NSAIDs]
including aspirin). In clinical practice, however, the
drugs that may be causing constipation may need to be
continued in spite of their negative effects on bowel
function. In constipation care studies, it was concluded
that the nursing staffs’ performance of constipation
care-related tasks was time consuming and costly in the
long-term care setting [4].
LAB are currently used in the prevention and treatment
of disease [5,6], specifically in the intestinal environment,
by inhibiting harmful bacteria through the lowering of the
intestinal pH, vitamin synthesis and blood cholesterol
levels. LAB are also used to treat intestinal disorders [7],
for improving lactose malabsorption and immune function
[8], prevention of cancer [9] and particularly to improve
diarrhea or constipated conditions [7].
In the present study, we used LAB supplements con-
taining Lactobacillus acidophilus (affects acute diarrhea
and colitis), Pediococcus pentosaceus (has anti-viral
effects), and Bifidobacterium longum SPM1205 (demon-
strates in vivo inhibitory effects on harmful enzyme
activities of intestinal microflora) to demonstrate any
potential probiotic activity [10-12].
We aimed to investigate the efficacy of this LAB sup-




The origins of the strains used in this study are shown
in Table 1. For isolated of Bifidobacteria, fecal samples
of healthy Koreans (20-30 years old) were collected by
BBL’s anaerobic sample collection and transport sys-
tem to maintain anaerobic conditions, and were used
within 24 h. Fecal samples were serially diluted 10-fold
from 10-1 to 10-8, and 100 μl was spread onto selective
BL (Blood Liver) (Nissui Pharm. Co. Ltd., Japan) agar
containing 5% sheep blood. After 48 hr of incubation
in anaerobic conditions (90% N2, 5% H2, 5% CO2)
(Bactron Anaerobic Chamber, Sheldon Manufacturing
Inc., USA) at 37°C, brown or reddish-brown colonies
2-3 mm in diameter were selected for further identifi-
cation [13].
A fructose-6-phosphate phosphoketolase (F6PPK) test
was performed [14] to ensure that the colonies selected
were Bifidobacteria. To identify the isolated Bifidobac-
terium spp. at the species level, 16S rRNA sequencing
was performed by Bioleaders (Daejeon, Korea).
Participants
All the participants were recruited from the Eden Adven-
tist Hospital in Gyeonggi-do, Korea. Male and female
nursing home residents with chronic constipation, and
who were presently receiving intervention (eg. laxatives,
enemas and other invasive procedures, such as manual
removal of fecal impaction) were evaluated for enrolment
in the study. Because a significant number of the study
participants were nursing home residents, it was not
always feasible to obtain a diagnosis according to “Rome
II” criteria for constipation as a prerequisite for the inclu-
sion criteria. Such a diagnosis would require a level of
communication with the patient that was not always pos-
sible in this study. The exclusion criteria were partici-
pants with ileus, renal failure, dialysis, Crohn’s disease,
ulcerative colitis and chronic abdominal pain. Thus, we
screened 25 participants and included 8 male and 11
female participants that chose to participate in the study.
Treatment
This study was designed to assess the effects of LAB (3.0
× 1011 CFU/g) in the regimen of nursing home residents
suffering from chronic constipation, the dispensing of
standard treatment by nursing home staffs and on costs
of care and medications. Participants with chronic con-
stipation were defined as residents who used laxatives at
least once a week.
The study protocol and the informed consent forms
were reviewed and approved by the Eden Adventist Hos-
pital. Each participant, or his or her legal guardian, was
informed both orally and in writing. Written informed
consent was obtained from all participants, or from their
legal guardians, before participation in the study.
Subjects were instructed on the aim and content of the
trial, as well as test methods. All 19 subjects were assigned
to receive LAB twice (to be taken 30 minutes after break-
fast and dinner) a day for 2 weeks in November 2008.
During the trial period, the participants were prohibited
from administering their existing laxative medications
and/or enemas in addition to the investigational product.
Questionnaire
Before entering the trial, the subjects completed a ques-
tionnaire on name, age, sex and current defecation
habits such as frequency of defecation in four steps
Table 1 List of LAB used in this study
Bacterial strains Source Origin
Lactobacillus acidophilus (LH) CBTa Commercial NAb
Pediococcus pentosaceus (PP) CBT Commercial NA
Bifidobacterium longum SPM 1205 Isolatec Human feces
aPurchased from CellBioTech, Kimpo, Kyunggido, Korea.
bNot available.
cIsolated from healthy Korean.
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from ‘once more than three days’ to ‘more than twice a
day’, amount of stool in three steps from ‘large’ to
‘small’, state of stool in five steps from ‘like stone’ to
‘like water’ and yes or no about ‘currently taking any
medicine for defecation’ (Appendix 1).
Subjects were observed for any untoward symptoms
such as vomiting, diarrhea or abdominal pain. The nur-
sing home staff recorded a defecation habit diary during
the study and this included information such as fre-
quency of defecation as well as amount and state of
stool passed by the subjects.
After ending the trial, the subjects draw up a ques-
tionnaire on defecation habits.
Fecal LAB levels
We collected fecal samples from the subjects both
before entering and after ending the trial, to investigate
LAB levels and harmful enzyme activity.
Fecal samples (0.1 g) were suspended in 0.9 ml of 0.1
M phosphate buffer (pH 6.8 containing 0.5% cysteine)
using a vortex, and 0.1 ml was then serially diluted 10-
fold from 10-1 to 10-7. 1 ml was then poured into selec-
tive MRS broth (pH 7.0) (Difco, USA). After 48 h of
incubation under anaerobic conditions (90% N2, 5% H2,
5% CO2) (Bactron Anaerobic Chamber, Sheldon MFG.
Inc., USA), colonies were counted as LAB [12]. The
numbers of colony forming units (CFU) are expressed
as log10 CFU per gram.
Harmful enzyme activities of intestinal microflora
Harmful enzyme activities such as b-glucosidase, b-glu-
curonidase, tryptophanase, and urease of intestinal
microflora related to colon cancer were tested in human
fecal samples as previously described [15-17].
Assay of b-glucosidase activity
b-glucosidase activity was assayed using 2 ml of a reac-
tion mixture containing 0.8 ml of 2 mM p-nitrophenyl-
b-D-glucopyranoside and 0.2 ml of the enzyme solution
(suspended fecal sample), incubated for 30 min at 37°C,
and then stopped by adding 1 ml of 0.5 N NaOH. The
reaction mixture was then centrifuged at 3,000 rpm for
10 min. Enzyme activity was measured by monitoring
absorbance at 405 nm.
Assay of b-glucuronidase activity
b-glucuronidase activity was assayed using 2 ml of a
reaction mixture consisting of 0.8 ml of 2 mM p-nitro-
phenyl-b-D-glucuronide and 0.2 ml of the enzyme
solution, incubated for 30 min at 37°C, and then
stopped by adding 1 ml of 0.5 N NaOH. The reaction
mixture was centrifuged at 3,000 rpm for 10 min.
Enzyme activity was measured by monitoring absor-
bance at 405 nm.
Assay of tryptophanase activity
Tryptophanase activity was assayed using 2.5 ml of a
reaction mixture consisting of 0.2 ml of complete
reagent solution (2.75 mg of pyridoxal phosphate, 19.6
mg of disodium EDTA dihydrate, and 10 mg of bovine
serum albumin in 100 ml of 0.05 M potassium phos-
phate buffer, pH 7.5), 0.2 ml of 20 mM tryptophan, and
0.1 ml of the enzyme solution, incubated for 1 h at 37°
C, and then stopped by adding 2 ml of color reagent
solution (14.7 g p-dimethylaminobenzaldehyde in 52 ml
H2SO4 and 948 ml 95% ethanol). The reaction mixture
was then centrifuged at 3,000 rpm for 10 min. Enzyme
activity was measured by monitoring absorbance at
550 nm.
Assay of urease activity
Urease activity was assayed using 0.5 ml of a reaction
mixture consisting of 0.3 ml of urea substrate solution
(4 mM urea in 20 mM sodium phosphate buffer, pH
7.0) and 0.1 ml of the enzyme solution, incubated for 30
min at 37°C and then stopped by adding 0.1 ml of 1 N
(NH4)2SO4. Phenolnitroprusside reagent (1 ml) and
alkaline hypochlorite reagent (NaClO, 1 ml) were added
to the stopped reaction mixture and incubated for 20
min at 65°C. The reaction mixture was centrifuged at
3,000 rpm for 10 min. Enzyme activity was measured by
monitoring absorbance at 603 nm.
Statistical analysis
The data were collected and analyzed independently of
the investigators, who did not have access to it or to its
analysis. Analysis data of questionnaire were processed
using the SAS, and comparisons data of fecal LAB levels
and harmful enzyme activity of intestinal microflora were
analyzed using the unpaired Student’s t-test. Differences
were considered statistically significant at p < 0.05.
Results
Analysis of questionnaire
This study tested 19 subjects with a mean age of 77.1
and suffering from chronic constipation; 8 males of
mean age 77.4 and 11 females of mean age 76.9. Of
these subjects, only 15 subjects (79%) were currently
receiving intervention such as laxatives and/or enemas:
8 males (100%) and 7 females (64%) (Table 2).
Table 2 Fundamental characteristic of subjects
Total Male Female
Number 19 8 11
Age 77.1 ± 10.1a 77.4 ± 10.7 76.9 ± 10.2
Interventionb 15 (79%) 8 (100%) 7 (64%)
aEach value provided is the mean ± standard deviation.
bLaxatives, enemas and other invasive procedures, such as manual removal of
fecal impaction.
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All 19 subjects were assigned to receive LAB (3.0 ×
1011 CFU/g) twice (to be taken 30 minutes after break-
fast and dinner) a day for 2 weeks, and answered their
defecation habits as follows; frequency of defecation: 11
individuals reported ‘once more than three days’
(57.9%), 3 ‘once two days’ (15.8%), 4 ‘once a day’ (21.1%)
and 1 ‘more than twice a day’ (5.3%) before LAB treat-
ment; 6 ‘once more than three days’ (31.6%), 7 ‘once
two days’ (36.8%), 6 ‘once a day’ (31.6%) and 0 ‘more
than twice a day’ (0.0%) after LAB treatment; amount of
stool: 4 individuals reported ‘large’ (21.1%), 11 ‘medium’
(57.9%) and 4 ‘small’ (21.1%) before LAB treatment; 8
‘large’ (42.1%), 9 ‘medium’ (47.4%) and 2 ‘small’ (10.5%)
after LAB treatment; state of stool: 1 individual reported
‘like stone’ (5.3%), 5 ‘hard’ (26.3%), 12 ‘soft’ (63.2%), 1
‘watery’ (5.3%) and 0 ‘like water’ (0.0%) before LAB
treatment; 0 ‘like stone’ (0.0%), 6 ‘hard’ (31.6%), 11 ‘soft’
(57.9%), 2 ‘watery’ (10.5%) and 0 ‘like water’ (0.0%) after
LAB treatment (Table 3).
According to the defecation habit diary recorded by
the nursing home staff, frequency of defecation (p =
0.676), amount of stool (’large’; p = 1, ‘medium’; p =
0.664 and ‘small’; p = 0.289) and state of stool (’like
stone’; p = 0, ‘hard’; p = 0.109, ‘soft’; p = 0.365, ‘watery’;
p = 0.377 and ‘like water’; p = 0) were not statistically
significant (Table 4).
Fecal LAB levels
Fecal LAB levels were significantly increased from 4.4
log10 CFU/g to 7.3 log10 CFU/g after LAB treatment
(p = 0.024) (Fig. 1.).
Harmful enzyme activities of intestinal microflora
The harmful enzyme activities of intestinal microflora
were shown in Table 5. After LAB treatment, tryptopha-
nase and urease activities were decreased by 43% and
30%, respectively. Furthermore, there was a statistically
significant decrease in both tryptophanase (p = 0.047)
and urease (p = 0.005) activities. However, b-glucosidase
and b-glucuronidase activities were increased, and there
was not a statistically significant increase in both b-glu-
cosidase (p = 0.074) and b-glucuronidase (p = 0.061)
activities.
Discussion
The composition of fecal microbiota, harmful enzyme
activities such as b-glucosidase, b-glucuronidase, trypto-
phanase, and urease of intestinal microflora, fecal fre-
quency, and consistency were determined [18].
Table 3 Analysis of questionnaire before and after LAB
treatment
Beforea Afterb





11 (57.9) 06 (31.6)
Once two days 03 (15.8) 07 (36.8)
Once a day 04 (21.1) 06 (31.6)
More than twice a
day
01 (05.3) 00 (00.0)
Amount of stool Large 04 (21.1) 08 (42.1)
Medium 11 (57.9) 09 (47.4)
Small 04 (21.1) 02 (10.5)
State of stool Like stone 01 (05.3) 00 (00.0)
Hard 05 (26.3) 06 (31.6)
Soft 12 (63.2) 11 (57.9)
Watery 01 (05.3) 02 (10.5)
Like water 00 (00.0) 00 (00.0)
aBefore the experiment started.
bAt the end of experiment.
Table 4 Analysis of defecation habit diary before, during and after LAB treatment
Variables Total Befored Duringe Afterf p valueb
Frequency of defecation
Frequency 3.71 ± 2.23a 3.33 ± 2.50 4.07 ± 2.37 3.73 ± 1.87 NSc
Amount of stool
Large 0.07 ± 0.25 0.07 ± 0.26 0.07 ± 0.26 0.07 ± 0.26 NS
Medium 2.76 ± 2.29 2.53 ± 2.72 2.53 ± 2.42 3.20 ± 1.70 NS
Small 0.89 ± 1.79 0.73 ± 1.79 1.47 ± 2.23 0.47 ± 1.13 NS
State of stool
Hard 0.78 ± 1.26 0.47 ± 1.06 1.33 ± 1.72 0.53 ± 0.64 NS
Normal 2.40 ± 2.29 2.40 ± 2.53 1.80 ± 2.24 3.00 ± 2.07 NS
Watery 0.53 ± 1.44 0.47 ± 0.83 0.93 ± 2.28 0.20 ± 0.56 NS
aEach value provided is the mean ± standard deviation.
bSignificance from each other at p < 0.05 as determined by Duncan’s multiple-range test.
cNS: not significant.
dBefore the experiment started.
eDuring the experiment period.
fAt the end of experiment.
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For this reason, we analyzed the questionnaire and
tested the fecal LAB levels and harmful enzyme activities
during the trials. The results showed that there were no
significant changes in defecation habits, but there was an
increase in the frequency of defecation and amount of
stool excreted, after LAB treatment. In frequency of defe-
cation, ‘once more than three days’ was decreased from 11
(57.9%) to 6 (31.6%), whereas ‘once two days’ and ‘once a
day’ were increased from 3 (15.8%) to 7 (36.8%) and from
4 (21.1%) to 6 (31.6%), respectively. In amount of stool,
‘small’ was decreased from 4 (57.9%) to 2 (31.6%), whereas
‘large’ was increased from 4 (21.1%) to 8 (42.1%).
We also found that fecal LAB levels were significantly
increased from 4.4 log10 CFU/g to 7.3 log10 CFU/g
after LAB treatment (p = 0.024). That is, LAB survive
passage through the upper-gastrointestinal tract after
oral feeding [19], and LAB treatment affects the intest-
inal environment to favor LAB colonization. Ingested
LAB produce lactate and SCFA (Short-Chain Fatty
Acids), which can improve constipation via changes in
intestinal microflora [20].
Harmful enzyme activities of intestinal microflora can
implicate enterohepatic circulation of toxic and carcino-
genic substances [21]. The results of the present study
showed a significant decrease in the activities of trypto-
phanase and urease, which are harmful enzymes com-
prising the intestinal microflora, by 43% and 30% in
subjects after LAB treatment, respectively (p values are
0.047 and 0.005). Thus, LAB may be potentially benefi-
cial as functional probiotics in preventing colon cancer
because of their inhibitory effects on harmful enzyme
activities of intestinal microflora.
It would appear that one of the shortcomings of this
study was that it was not conducted as a randomized,
double-blind, placebo-controlled study. However, this
was not possible given the serious health conditions and
the number of subjects involved in the study.
Another possible limitation of this study was that
while the difference in frequency of defecation, amount,
and state of stool were evaluated, other potentially
related variables such as time and sense of defecation
were not evaluated. This was because of the difficulties
in conversing with several subjects and the time and
work-restrictions of the nursing home staff members.
LAB affected the intestinal environment by producing a
clinically relevant difference in defecation habits, fecal
LAB levels and harmful enzyme activities of intestinal
microflora. Also, we encountered no adverse events with
the daily use of LAB, which can be used alone or in com-
bination with other previously mentioned interventions.
Figure 1 Changes of total LAB levels in subjects. All 19 subjects were orally administered twice (to be taken 30 minutes after breakfast and
dinner) a day for 2 weeks with LAB (3.0 × 1011 CFU/g). Before: before the experiment started, After: at the end of experiment. Data are
presented as means and standard deviation. *p < 0.05 statistically significant compared with before LAB treatment.
Table 5 In vivo inhibitory effects of LAB on fecal harmful
enzymes in subjects
Period
Activity (%) Befored Aftere p valueb
b-glucosidase 1.60 ± 1.05a 2.44 ± 1.05 NSc
b-glucuronidase 1.29 ± 0.76 2.08 ± 1.07 NS
Tryptophanase 0.41 ± 0.25 0.23 ± 0.06 0.0473
Urease 0.46 ± 0.10 0.32 ± 0.11 0.0051
aEach value provided is the mean ± standard deviation.
bSignificance from each other at p < 0.05 as determined by Duncan’s
multiple-range test.
cNS: not significant.
dBefore the experiment started.
eAt the end of experiment.
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Thus, the results of this study showed that the LAB
supplement tested, produced positive effects on the
management of nursing home residents with chronic
constipation.
Conclusions
The present study demonstrated that LAB improves
defecation habit (frequency of defecation, amount and
state of stool) in nursing home residents with chronic
constipation. In addition, this LAB improved the balance
the intestinal microflora, which exert beneficial effects
by decreasing harmful enzymes activities such as tryto-
phanase and urease. Furthermore, it also affects the
intestinal environment, through increase of fecal LAB
levels. Therefore, LAB may be used as functional pro-
biotics to improve human health by the management of
constipation, helping to prevent colon cancer. Thus, the
results of this study warrant follow-up with a larger
multicenter study to further assess efficacy.
Appendix 1 - Questionnaire
Name: ( )
Age: ( )
Sex: Male ( ), Female ( )
* Before LAB treatment *
The following list shows the questions about currently
your defecation habits.
1. Frequency of defecation?
①Once more than three days ②Once two days
③Once a day ④More than twice a day
2. Amount of stool?
①Large ②Medium ③Small
3. State of stool?
①Like stone ②Hard ③Soft ④Watery ⑤Like water
4. Are you currently take any medicine for defecate
the stool?
①Yes (What is it? ) ②No
* After LAB treatment *
The following list shows the questions about your defe-
cation habits after LAB treatment.
1. Frequency of defecation?
①Once more than three days ②Once two days
③Once a day ④More than twice a day
2. Amount of stool?
①Large ②Medium ③Small
3. State of stool?
①Like stone ②Hard ③Soft ④Watery ⑤Like water
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